title: Inhibition of proliferation, invasion, and migration of prostate cancer cells by downregulating elongation factor-1alpha expression.
abstract: Overexpression of elongation factor-1alpha (EF-1alpha) has been reported to contribute to the development and progression of various cancers. However, its role in prostate cancer (PCa) still remains poorly understood. In the present study, we investigate the influence of EF-1alpha in Du145, a high-grade metastatic PCa cell line, and demonstrate that EF-1alpha plays an essential role in cellular properties associated with tumor progression, namely cell proliferation, invasion, and migration. In this study, EF-1alpha expression in human PCa cell line Du145 was reduced by RNA interference (RNAi) technology, and the proliferation, invasion, and migration of EF-1alpha-reduced Du145 cells were examined. We also detected an EF-1alpha expression pattern in 20 pairs of primary PCa samples and their corresponding normal tissues. Expression of EF-1alpha was detectable in four PCa cell lines (22RV1, LnCap, Du145, and PC3), indicating its possible role in pathogenesis of PCa. RNAi-mediated knockdown of EF-1alpha expression in Du145 cells, which expressed the highest level of EF-1alpha among four PCa cell lines, led to a decrease in proliferation. Similarly, suppression of EF-1alpha inhibited Du145 cell migration and invasion through a basement membrane substitute. Furthermore, we found that the normal prostate tissues showed a relatively low level of EF-1alpha expression, whereas PCa tissues demonstrated significantly higher expression levels of EF-1alpha (P < 0.001). Taken together, these findings support the hypothesis that EF-1alpha affects multiple processes involved in tumor progression, and identify EF-1alpha as a potential therapeutic target.
authors.affiliation: Department of Urology, Beijing Hospital MH, Beijing, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Zhu
authors.forename: Wei
authors.initials: W
authors.lastname: Yan
authors.forename: Hui-chan
authors.initials: HC
authors.lastname: He
authors.forename: Xue-cheng
authors.initials: XC
authors.lastname: Bi
authors.forename: Zhao-dong
authors.initials: ZD
authors.lastname: Han
authors.forename: Qi-shan
authors.initials: QS
authors.lastname: Dai
authors.forename: Yong-kang
authors.initials: YK
authors.lastname: Ye
authors.forename: Yu-xiang
authors.initials: YX
authors.lastname: Liang
authors.forename: Jianye
authors.initials: J
authors.lastname: Wang
authors.forename: Weide
authors.initials: W
authors.lastname: Zhong
mesh_terms: D048708:Cell Growth Processes / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D015536:Down-Regulation; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009361:Neoplasm Invasiveness; D020648:Peptide Elongation Factor 1 / Q000235:genetics / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics; D015203:Reproducibility of Results
chemical_list: D020648:Peptide Elongation Factor 1; D034741:RNA, Small Interfering
references.citation: J Biol Chem. 1993 Jan 5;268(1):392-8
references.pmid: 8380160
references.citation: Prostate. 2002 Jun 1;51(4):247-55
references.pmid: 11987153
references.citation: Anal Biochem. 1976 May 7;72:248-54
references.pmid: 942051
references.citation: J Surg Res. 2010 May 15;160(2):260-7
references.pmid: 19286191
references.citation: Oral Oncol. 2006 Mar;42(3):240-56
references.pmid: 16266819
references.citation: Prostate. 2006 Nov 1;66(15):1641-52
references.pmid: 16927306
references.citation: Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4991-5
references.pmid: 2052582
references.citation: Trends Biochem Sci. 1995 May;20(5):169-70
references.pmid: 7610475
references.citation: Science. 2002 Jan 25;295(5555):694-7
references.pmid: 11809977
references.citation: Cancer Res. 2006 Sep 15;66(18):9065-73
references.pmid: 16982748
references.citation: Nature. 2001 Jan 18;409(6818):363-6
references.pmid: 11201747
references.citation: Nature. 2001 May 17;411(6835):375-9
references.pmid: 11357145
references.citation: Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10233-8
references.pmid: 9294193
references.citation: Pathol Oncol Res. 2009 Sep;15(3):369-74
references.pmid: 19048397
references.citation: J Biol Chem. 1989 Dec 5;264(34):20518-25
references.pmid: 2511205
references.citation: J Biol Chem. 1983 Jan 10;258(1):24-6
references.pmid: 6336747
references.citation: Nature. 2001 May 24;411(6836):494-8
references.pmid: 11373684
references.citation: Cancer Res. 1991 Sep 15;51(18 Suppl):5054s-5059s
references.pmid: 1884381
references.citation: Hum Genet. 1987 Apr;75(4):339-44
references.pmid: 3570288
references.citation: Nature. 2001 Mar 1;410(6824):24-5
references.pmid: 11242022
references.citation: Nature. 2002 Jul 11;418(6894):244-51
references.pmid: 12110901
references.citation: Clin Cancer Res. 2001 Jul;7(7):1987-91
references.pmid: 11448915
references.citation: Nature. 1998 Feb 19;391(6669):806-11
references.pmid: 9486653
references.citation: J Biol Chem. 1995 Jun 23;270(25):15222-30
references.pmid: 7797506
references.citation: Science. 2000 Nov 10;290(5494):1159-62
references.pmid: 11073454
references.citation: N Engl J Med. 2003 Jul 24;349(4):366-81
references.pmid: 12878745
references.citation: Cancer Res. 2006 Mar 15;66(6):3071-7
references.pmid: 16540656
references.citation: Annu Rev Cell Biol. 1988;4:649-86
references.pmid: 2848555
references.citation: J Biol Chem. 1990 Feb 5;265(4):2286-91
references.pmid: 2404981
references.citation: J Cell Biol. 1994 Aug;126(4):863-76
references.pmid: 7914201
references.citation: Cell Motil Cytoskeleton. 1991;20(4):279-88
references.pmid: 1666339